MinervaX

Biotech · DK

Biotech developing a prophylactic vaccine against Group B Streptococcus (GBS).

Founders

Gunnar Lindahl (Sweden · ♂) — A Lund University microbiology professor whose research identified protective surface proteins of Group B Streptococcus, he spun that science out into MinervaX in 2010 to develop a GBS vaccine.
Thomas Areschoug (Sweden · ♂) — A Lund University researcher who worked with Lindahl on the GBS vaccine candidate, he co-founded MinervaX to commercialize the discovery.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Oct 2023	Funding round Danish biotech MinervaX raised an upsized EUR54M financing, with EQT Life Sciences and OrbiMed, to advance its Group B Streptococcus vaccine toward Phase III.	$58M
Dec 2022	Funding round Copenhagen biotech MinervaX raised EUR22M in equity, co-led by Trill Impact Ventures and Pureos Bioventures, to advance its Group B Streptococcus vaccine toward Phase 3.	$23.3M
Dec 2022	Debt MinervaX secured a debt facility of up to EUR50M from the European Investment Bank alongside its equity round.	$53M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.